[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fulcrum Therapeutics Inc (FULC)

Fulcrum Therapeutics Inc (FULC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 495,504
  • Shares Outstanding, K 66,600
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,880 K
  • EBIT $ -85 M
  • EBITDA $ -83 M
  • 60-Month Beta 3.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.20

Options Overview Details

View History
  • Implied Volatility 114.90% (-0.96%)
  • Historical Volatility 71.12%
  • IV Percentile 40%
  • IV Rank 22.85%
  • IV High 299.91% on 03/03/26
  • IV Low 60.11% on 08/20/25
  • Expected Move (DTE 16) 1.70 (23.48%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 5
  • Volume Avg (30-Day) 151
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 12,554
  • Open Int (30-Day) 12,257
  • Expected Range 5.54 to 8.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 6
  • High Estimate $-0.28
  • Low Estimate $-0.35
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) -10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.47 +10.20%
on 03/30/26
8.37 -14.81%
on 04/20/26
+0.40 (+5.94%)
since 03/27/26
3-Month
6.47 +10.20%
on 03/30/26
12.03 -40.73%
on 02/19/26
-3.81 (-34.83%)
since 01/29/26
52-Week
3.55 +100.85%
on 04/30/25
15.74 -54.70%
on 12/08/25
+3.48 (+95.34%)
since 04/29/25

Most Recent Stories

More News
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive...

FULC : 7.09 (-4.70%)
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve...

FULC : 7.09 (-4.70%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum?

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 7.09 (-4.70%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum?

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 7.09 (-4.70%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum?

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 7.09 (-4.70%)
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules...

FULC : 7.09 (-4.70%)
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease 

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of...

FULC : 7.09 (-4.70%)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...

FULC : 7.09 (-4.70%)
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules...

FULC : 7.09 (-4.70%)
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin...

FULC : 7.09 (-4.70%)

Business Summary

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 8.58
2nd Resistance Point 8.34
1st Resistance Point 7.89
Last Price 7.09
1st Support Level 7.20
2nd Support Level 6.96
3rd Support Level 6.51

See More

52-Week High 15.74
Fibonacci 61.8% 11.08
Fibonacci 50% 9.64
Fibonacci 38.2% 8.21
Last Price 7.09
52-Week Low 3.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.